NDA 019998 · Recordati Rare
Chemet
Succimer · Oral · Lead Chelator
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Sep 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Jan 30, 1991
Approved uses
1
Original approval plus efficacy supplements
Registered trials
7
1 Phase 3, 2 recruiting
FAERS reports
71
35 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 10, 2025.
CHEMET is indicated for the treatment of lead poisoning in pediatric patients aged 1 year and older with blood lead levels above 45 mcg/dL. CHEMET is a lead chelator indicated for the treatment of lead poisoning in pediatric patients aged 1 year and older with blood lead levels above 45 mcg/dL. ( 1 ) Limitations of Use CHEMET is not indicated for prophylaxis of lead poisoning in a lead-containing environment. ( 1 ) CHEMET does not cross the blood-brain barrier and is not indicated to treat encephalopathy associated with lead toxicity. ( 1 ) Limitations of Use CHEMET is not indicated for prophylaxis of lead poisoning in a lead-containing environment. CHEMET does not cross the blood-brain barrier and is not indicated to treat encephalopathy associated with lead toxicity.
Mechanism: Succimer is a lead chelator; it forms water soluble chelates and, consequently, increases the urinary excretion of lead.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 30, 1991 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- CHEMET · SUCCIMER 100MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Succimer" as an intervention, any sponsor and status, largest first.
- Treatment of Lead-Exposed Children TrialPivotal-lookingCompleted
National Institute of Environmental Health Sciences (NIEHS)NIH
NCT00342849 · 780 participants · Start Jul 15, 1994 · Primary completion Aug 29, 2007
Drug: Succimer; Placebo · For: Lead Exposure
Sites: Baltimore, Maryland; Newark, New Jersey; Columbus, Ohio · 4 sites in all
Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
NCT03957720 · 400 participants (planned) · Start Mar 15, 2019 · Primary completion Dec 31, 2024
Drug: DMPS; Penicillamine and 2 more · For: Wilson's Disease
Sites: Hangzhou, China
- Randomized Study of Succimer (Dimercaptosuccinic Acid) on Growth of Lead-Poisoned ChildrenPivotal-lookingCompleted
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00004838 · 175 participants · Start Sep 1997
Drug: succimer · For: Lead Poisoning
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06811233 · 140 participants (planned) · Start May 8, 2025 · Primary completion Aug 31, 2029
Drug: DMSA; Ca-EDTA and 2 more · For: Acute Myeloid Leukemia (AML)
Sites: Houston, Texas
Southwest College of Naturopathic MedicineAcademic, hospital or other
NCT00811083 · 80 participants · Start May 2005 · Primary completion Apr 2007
Drug: DMSA - dimercaptosuccinic acid · For: Autism
Sites: Tempe, Arizona
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03630991 · 58 participants (planned) · Start Oct 11, 2018 · Primary completion Apr 30, 2027
Drug: Edetate Calcium Disodium; Succimer · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 15 more
Sites: Houston, Texas
- Mercury Chelation to Treat AutismWithdrawn
National Institute of Mental Health (NIMH)NIH
NCT00376194 · 0 participants · Start Sep 2006
Drug: DMSA · For: Autism; Asperger's Disorder; Child Development Disorders, Pervasive
Sites: Bethesda, Maryland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use23
- product availability issue9
- arthralgia6
- hypertension5
- no adverse event5
- weight increased5
- condition aggravated4
- dizziness4
- skin striae4
- abdominal pain upper3
- arrhythmia3
- asthenia3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 4 |
| 2011 | 1 |
| 2012 | 3 |
| 2014 | 1 |
| 2016 | 15 |
| 2017 | 7 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 16 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 4 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Chemet (Succimer)
2024 spending
$92K
Beneficiaries
27
44 claims
Per beneficiary
$3,393
$21.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $286,690 |
| 2021 | $69,032 |
| 2022 | $272,862 |
| 2023 | $152,630 |
| 2024 | $91,613 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effects of succimer on the absorption of lead in adults determined by using the stable isotope 204Pb.
Smith DR, Markowitz ME, Crick J, et al. · Environ Res 1994 · Clinical Trial, Randomized Controlled Trial
- A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders.
Geier DA, Geier MR · Neuro Endocrinol Lett 2006 · Clinical Trial, Research Support, Non-U.S. Gov't
- Effect of succimer on growth of preschool children with moderate blood lead levels.
Peterson KE, Salganik M, Campbell C, et al. · Environ Health Perspect 2004 · Clinical Trial, Multicenter Study
- Efficacy of succimer chelation of mercury at background exposures in toddlers: a randomized trial.
Cao Y, Chen A, Jones RL, et al. · J Pediatr 2011 · Multicenter Study, Randomized Controlled Trial
- Do children with falling blood lead levels have improved cognition?
Liu X, Dietrich KN, Radcliffe J, et al. · Pediatrics 2002 · Clinical Trial, Comparative Study
- Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies.
Appenzeller-Herzog C, Mathes T, Heeres MLS, et al. · Liver Int 2019 · Comparative Study, Meta-Analysis
Sponsor: Recordati Rare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.